Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: This phase I trial is studying the side effects and best dose of
17-N-allylamino-17-demethoxygeldanamycin in treating patients with refractory advanced solid
tumors or hematologic cancers.